logo

Axcella Health Inc (AXLA)



Trade AXLA now with
  Date
  Headline
11/2/2022 10:27:18 AM Wedbush Is Increasing Axcella Health Inc (AXLA) FY23 Estimate To -1.18 From -1.41
11/2/2022 10:27:06 AM Wedbush Is Increasing Axcella Health Inc (AXLA) Q4 23 Estimate To -0.33 From -0.39
11/2/2022 10:26:56 AM Wedbush Is Raising Axcella Health Inc (AXLA) Q3 23 Estimate To -0.30 From -0.36
11/2/2022 10:26:30 AM Wedbush Is Raising Axcella Health Inc (AXLA) Q2 23 Estimate To -0.28 From -0.34
11/2/2022 10:26:19 AM Wedbush Is Raising Axcella Health Inc (AXLA) Q1 23 Estimate To -0.26 From -0.32
11/2/2022 10:26:07 AM Wedbush Is Increasing Axcella Health Inc (AXLA) FY22 Estimate To -1.45 From -1.57
11/2/2022 10:25:56 AM Wedbush Is Raising Axcella Health Inc (AXLA) Q4 22 Estimate To -0.25 From -0.30
11/2/2022 10:25:27 AM Wedbush Reiterates Axcella Health Inc (AXLA) At Outperform With $6 Price Target
11/1/2022 7:18:26 AM Axcella Therapeutics Q3 Net Loss/shr $0.34 Vs. Loss/shr $0.41 Last Year
10/13/2022 8:05:27 AM Axcella Announces $34.2 Mln Registered Direct Offering Of Common Stock Priced At Market
9/29/2022 6:09:32 AM Axcella Announces Positive Interim Data From Phase 2b EMMPACT Study Of AXA1125 In Nonalcoholic Steatohepatitis
8/12/2022 7:33:45 AM Axcella Therapeutics Q2 Net Loss/shr $0.40 Vs. Loss/shr $0.42 Last Year
8/2/2022 6:11:16 AM Axcella Reports Highly Promising Results From Phase 2a Placebo Controlled Clinical Trial For Long COVID
5/5/2022 7:15:12 AM Axcella Therapeutics Q1 Net Loss $19.0 Mln Or $0.46/shr Vs Net Loss Of $15.2 Mln Or $0.40/shr Prior Year
6/30/2021 7:46:13 AM Axcella Initiates Phase 2 Trial Of AXA1665, Oral Product Candidate For Reduction In Risk Of Recurrent OHE